{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T16:39:04Z","timestamp":1779208744784,"version":"3.51.4"},"reference-count":45,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007655","name":"Aichi Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K07162"],"award-info":[{"award-number":["22K07162"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K19472"],"award-info":[{"award-number":["22K19472"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008886","name":"Princess Takamatsu Cancer Research Fund","doi-asserted-by":"publisher","award":["22\u201025417"],"award-info":[{"award-number":["22\u201025417"]}],"id":[{"id":"10.13039\/501100008886","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Mesothelioma is a neoplastic disease associated with asbestos exposure. It is highly malignant and has a poor prognosis; thus, early detection is desirable. Recent whole\u2010genome analysis has revealed that mesothelioma is characterized by a high frequency of mutations in a set of genes involved in the Hippo pathway, such as <jats:italic>NF2<\/jats:italic> and <jats:italic>LATS2<\/jats:italic>. However, a rapid, simple, and precise method for finding mesothelioma with these mutations has not yet been established.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Clustering of Hippo pathway gene alteration groups and the differential expression of each gene in mesothelioma patients were analyzed using The Cancer Genome Atlas database. Gene expression levels in various tumors and normal tissues were analyzed using public databases. Knockdown or transient expression of <jats:italic>YAP1<\/jats:italic> or <jats:italic>TAZ<\/jats:italic> was performed to evaluate the regulation of gene expression by these genes. NT\u2010proBNP was measured in the pleural effusions of 18 patients and was compared with NF2 expression in five cases where cell lines had been successfully established.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p><jats:italic>NPPB<\/jats:italic> mRNA expression was markedly higher in the group of mesothelioma patients with Hippo pathway gene mutations than in the group without them. <jats:italic>NPPB<\/jats:italic> expression was low in all normal tissues except heart, and was highest in mesothelioma. Mesothelioma patients in the high <jats:italic>NPPB<\/jats:italic> expression group had a significantly worse prognosis than those in the low <jats:italic>NPPB<\/jats:italic> expression group. <jats:italic>NPPB<\/jats:italic> expression was suppressed by knockdown of <jats:italic>YAP1<\/jats:italic> or <jats:italic>TAZ<\/jats:italic>. NT\u2010proBNP was abundant in the effusions of mesothelioma patients and was particularly high in those with impaired NF2 expression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p><jats:italic>NPPB<\/jats:italic>, whose levels can be measured in pleural effusions of mesothelioma patients, has the potential to act as a biomarker to detect <jats:italic>NF2<\/jats:italic>\u2010Hippo pathway gene alterations and\/or predict patient prognosis. Additionally, it may provide useful molecular insights for a better understanding of mesothelioma pathogenesis and for the development of novel therapies.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.6056","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T09:01:16Z","timestamp":1683795676000},"page":"13586-13598","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Aberrant expression of <scp><i>NPPB<\/i><\/scp> through <scp>YAP1<\/scp> and <scp>TAZ<\/scp> activation in mesothelioma with Hippo pathway gene alterations"],"prefix":"10.1002","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0689-1794","authenticated-orcid":false,"given":"Tatsuhiro","family":"Sato","sequence":"first","affiliation":[{"name":"Division of Cancer Biology Aichi Cancer Center Research Institute  Nagoya Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Akao","sequence":"additional","affiliation":[{"name":"Division of Cancer Biology Aichi Cancer Center Research Institute  Nagoya Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayuko","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Molecular Pathology, School of Medicine Hyogo Medical University  Hyogo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tohru","family":"Tsujimura","sequence":"additional","affiliation":[{"name":"Department of Molecular Pathology, School of Medicine Hyogo Medical University  Hyogo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satomi","family":"Mukai","sequence":"additional","affiliation":[{"name":"Division of Cancer Biology Aichi Cancer Center Research Institute  Nagoya Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"Sekido","sequence":"additional","affiliation":[{"name":"Division of Cancer Biology Aichi Cancer Center Research Institute  Nagoya Japan"},{"name":"Division of Molecular and Cellular Oncology Nagoya University Graduate School of Medicine  Nagoya Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,5,11]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.136"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32714-8"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.11.005"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2017-0124-RA"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3520"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0804"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncy.21928"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/pin.12453"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2018-0273-OA"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.12.014"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2015-0508-LE"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19040988"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/embor.2012.11"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2014.04.001"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.42"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-2164"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgw084"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-018-0417-7"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2012.5"},{"issue":"12","key":"e_1_2_12_21_1","first-page":"4399","article-title":"The novel potent TEAD inhibitor, K\u2010975, inhibits YAP1\/TAZ\u2010TEAD protein\u2010protein interactions and exerts an anti\u2010tumor effect on malignant pleural mesothelioma","volume":"10","author":"Kaneda A","year":"2020","journal-title":"Am J Cancer Res"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-20-0717"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107809"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(83)91675-3"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(84)91077-5"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/313397a0"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/332078a0"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.2741\/1613"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199807303390507"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.90.1.195"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.28.6.988"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.10.1252"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011053"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042330"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/resp.13788"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-02248-5"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15025"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4107"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2020-0610"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1005465"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2018.11.010"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2021.04.015"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.25.2.227"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.09.026"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-019-0309-6"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-2586"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.6056","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T13:01:28Z","timestamp":1699362088000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.6056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,11]]},"references-count":45,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1002\/cam4.6056"],"URL":"https:\/\/doi.org\/10.1002\/cam4.6056","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,11]]},"assertion":[{"value":"2023-01-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}